<unk>  is a kinase inhibitor that is FDA approved for the treatment of patients with unresectable or metastatic melanoma with [[BRAF|BRAF V600E mutation]] as detected by an FDA-approved test.   Common adverse reactions include arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma.
Vemurafenib
Enasidenib
Fostamatinib
Neratinib
Encorafenib
Brigatinib
Regorafenib
Sunitinib